May 14, 2014
11:00 am to 12:00 pm

Sponsored by

Webinar Description:

Most of the CHO-base transient gene expression (TGE) systems are based on engineered CHO cells, unique expression constructs, or specialize regents. These systems, as well highly optimized protocols for lipids and polyethylenimine, have varying levels of reproducibility, scalability, and cost effectiveness, and in general produce antibody titers from 10 to 100 mg/L for typical IgG. They have an even lower expression levels for difficult-to-express cells.

The MaxCyte flow electroporation platform provides a universal means of fully scalable, highly efficient transient transfection for rapid high titer antibody production in CHO cells, often >1 gram/Liter with optimization. All without the use of specialized reagents, expression vectors, or engineered CHO cell lines. Having adequate quantities of antibodies earlier for characterization and proof of concept studies can accelerate and improve candidate selection. Additionally, the platform can also be used to produce other proteins and works with a variety of other cell types like HEK, Vero, CAP-T®, insect cells, primary cells, stem cells, and other difficult-to-transfect cells. The same technology can also generate transfected cells with high viability and transfection efficiency for stable pools and for the selection and rapid generation of high yield stable clones, thus bridging the gap between early and late stage antibody development activities.

Learning Objectives:

  • Gain a familiarity with scalable flow transfection
  • Learn how to generate large quantities of protein quickly
  • Discover how to accelerate product development
  • Understand the difference between electroporation as a consistent, reproducible transfection method compared with chemical methods
  • Learn how to rapidly obtain high expression with difficult-to-express proteins


James Brady, Ph.D., MBA. Director of Technical Applications, MaxCyte, Inc.
James BradyJames Brady, Ph.D., is Director of Technical Applications at MaxCyte, Inc, where he has worked since 2004. Prior to joining MaxCyte, Dr, Brady was a Senior Scientist at Genetic Therapy, Inc. (a Novartis subsidiary) and a Group Leader at MetaMorhpix, Inc. Dr. Brady earned a B.S. in Biology from the College of William and Mary and a Ph.D. in Genetics from Indiana University. He also received postdoctoral training in the National Eye Institute of the National Institutes of Health.

Jérôme Courtête, Ph.D., Head of Protein Production and Purification Group, Valneva, Inc.
Jerome CourteteJérômeCourtêtejoined Valneva (formerly known as Vivalis)in July 2009 as a project leader working on the development of the EBx platform for the production of therapeutic monoclonal antibodies. Since November 2012, he has been managing the R&D protein production group, specifically in charge of the production/purification/characterization of recombinant proteins on CHO-based expression platform to support clients’ projects or internal requirements. TheValneva CHO platform has a robust and reliable process for generating stable clones expressing recombinant proteins up to bioreactor levels. In addition, Valneva have developed a production process for large-scale transient expression (based on MaxCyte STX technology) thatenables a quick response to internal requirements but also and especially to those from the VIVA | SCREEN (the fully human monoclonal antibody discovery platform).

Audrey Angel, MSc., Research and Development Engineer, Valneva, Inc.
Audrey AngelAudrey Angel, R&D engineer, joined Valneva in 2008 after receiving her MSc in biotechnology from ESBS and three years in academic research in Bern, Germany. Ms. Angel has worked on the development of an automated process for EB66 cell line selection prior to contributing to Valneva's CHO platform creation. After implementation of a stable cell line selection process, she's now involved in transient protein production optimization for customer and internal projects, supporting the vivascreen antibody discovery platform.

Cost: No cost